Elizabeth Emilie Bailey
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Elizabeth Emilie Bailey’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A121963 · Current
Licensed to practise in California · since 2012 · expires 2028-01-31 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$32,150
Medicare paid this office $32,150 for 249 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 146 | $10,631 | $56 |
| Return visit (30+ min) | 36 | $4,583 | $94 |
| Destruction of skin growth, 1-14 growths | 48 | $3,581 | $62 |
| Destruction of precancer skin growth, 1 growth | 60 | $3,219 | $43 |
| New patient visit (30+ min) | 28 | $1,937 | $69 |
See all 10 services
| Short return visit (20+ min) | 146 | $10,631 | $56 |
| Return visit (30+ min) | 36 | $4,583 | $94 |
| Destruction of skin growth, 1-14 growths | 48 | $3,581 | $62 |
| Destruction of precancer skin growth, 1 growth | 60 | $3,219 | $43 |
| New patient visit (30+ min) | 28 | $1,937 | $69 |
| New patient visit (45+ min) | 15 | $1,893 | $126 |
| Biopsy of related skin growth, first growth | 55 | $1,706 | $28 |
| Short return visit | 39 | $1,321 | $31 |
| Biopsy of related skin growth, each additional growth | 13 | $337 | $18 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $299 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 210 | More than 80% of doctors who do this |
| Skin biopsy | 117 | More than 78% of doctors who do this |
Who their Medicare patients are
249 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 12% · Women 60% · Also on Medicaid 20% · Health risk score 1.20. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 60% · Coronary heart disease 22% · Diabetes 20% · Depression 19% · Cancer 17% · Chronic kidney disease 16% · Atrial fibrillation 12% · Heart failure 11% · COPD 10% · Dementia 7% · Stroke 6%.
The office billed $154,409, Medicare allowed $43,932 and paid $32,150; for 750 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 249 | 750 | 73 | 1.20 | $154,409 | $32,150 |
| 2023 | 142 | 357 | 74 | 1.01 | $63,970 | $15,202 |
| 2022 | 170 | 481 | 72 | 1.09 | $83,606 | $19,876 |
| 2021 | 170 | 508 | 73 | 1.11 | $101,217 | $21,982 |
| 2020 | 292 | 725 | 71 | 1.27 | $150,544 | $21,646 |
| 2019 | 447 | 1,772 | 72 | 1.14 | $246,550 | $55,586 |
| 2018 | 481 | 1,952 | 73 | 1.24 | $191,228 | $60,494 |
| 2017 | 310 | 1,017 | 73 | 1.12 | $167,300 | $42,377 |
| 2016 | 100 | 338 | 73 | 1.04 | $38,235 | $10,546 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Short return visit (20+ min) | 79 | $4,995 | $54 |
| Destruction of skin growth, 1-14 growths | 35 | $2,336 | $61 |
| Return visit (30+ min) | 26 | $2,179 | $81 |
| Destruction of precancer skin growth, 1 growth | 26 | $1,309 | $44 |
| New patient visit (30+ min) | 18 | $1,279 | $71 |
| Short return visit | 20 | $708 | $31 |
| Biopsy of related skin growth, first growth | 13 | $383 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 20 | $119 | $2 |
2022: 9 services
| Short return visit (20+ min) | 101 | $7,708 | $54 |
| Return visit (30+ min) | 31 | $2,951 | $80 |
| Destruction of skin growth, 1-14 growths | 34 | $2,116 | $54 |
| Destruction of precancer skin growth, 1 growth | 29 | $1,613 | $44 |
| New patient visit (30+ min) | 20 | $1,041 | $52 |
| Short return visit | 30 | $802 | $24 |
| Biopsy of related skin growth, first growth | 26 | $681 | $25 |
| New patient visit (15+ min) | 11 | $393 | $36 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $152 | $2 |
2021: 11 services
| Short return visit (20+ min) | 79 | $5,674 | $55 |
| Return visit (30+ min) | 42 | $4,712 | $86 |
| New patient visit (45+ min) | 20 | $2,225 | $111 |
| Destruction of skin growth, 1-14 growths | 27 | $2,071 | $58 |
| New patient visit (30+ min) | 20 | $1,438 | $72 |
| Destruction of precancer skin growth, 1 growth | 29 | $1,164 | $39 |
| Biopsy of related skin growth, first growth | 30 | $910 | $26 |
| Short return visit | 28 | $825 | $28 |
| Punch biopsy, first skin growth | 11 | $567 | $44 |
| Biopsy of related skin growth, each additional growth | 15 | $508 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $157 | $2 |
2020: 10 services
| Short return visit (20+ min) | 190 | $9,028 | $37 |
| Return visit (30+ min) | 25 | $2,095 | $65 |
| Destruction of precancer skin growth, 1 growth | 54 | $2,011 | $35 |
| New patient visit (15+ min) | 56 | $1,953 | $35 |
| New patient visit (30+ min) | 33 | $1,700 | $52 |
| Destruction of skin growth, 1-14 growths | 23 | $965 | $42 |
| Biopsy of related skin growth, first growth | 36 | $776 | $20 |
| Punch biopsy, first skin growth | 12 | $454 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $265 | $2 |
| Biopsy of related skin growth, each additional growth | 11 | $252 | $19 |
2019: 12 services
| Short return visit (20+ min) | 325 | $22,180 | $42 |
| Destruction of precancer skin growth, 1 growth | 112 | $6,435 | $42 |
| Destruction of skin growth, 1-14 growths | 76 | $5,846 | $57 |
| New patient visit (30+ min) | 85 | $4,749 | $56 |
| Biopsy of related skin growth, first growth | 91 | $2,443 | $23 |
| New patient visit (15+ min) | 62 | $2,134 | $34 |
| Return visit (30+ min) | 30 | $2,118 | $59 |
| Biopsy of related skin growth, each additional growth | 32 | $1,114 | $20 |
| Punch biopsy, first skin growth | 25 | $1,002 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 82 | $971 | $2 |
| Injection into skin growth, 1-7 growths | 15 | $616 | $24 |
| Punch biopsy, each additional skin growth | 14 | $298 | $21 |
2018: 10 services
| Short return visit (20+ min) | 311 | $19,749 | $43 |
| Destruction of precancer skin growth, 1 growth | 138 | $8,002 | $43 |
| New patient visit (30+ min) | 118 | $7,199 | $61 |
| Destruction of skin growth, 1-14 growths | 78 | $5,656 | $61 |
| Biopsy of single growth of skin and/or tissue | 139 | $5,475 | $31 |
| Return visit (30+ min) | 43 | $5,166 | $65 |
| New patient visit (15+ min) | 66 | $2,651 | $40 |
| Biopsy of each additional growth of skin and/or tissue | 44 | $1,544 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 107 | $1,259 | $2 |
| Injection into skin growth, 1-7 growths | 12 | $409 | $19 |
2017: 9 services
| New patient visit (30+ min) | 139 | $9,857 | $71 |
| Short return visit (20+ min) | 138 | $8,437 | $45 |
| Destruction of skin growth, 1-14 growths | 62 | $4,921 | $67 |
| Destruction of precancer skin growth, 1 growth | 79 | $3,734 | $41 |
| Biopsy of single growth of skin and/or tissue | 59 | $3,415 | $49 |
| Return visit (30+ min) | 24 | $3,012 | $77 |
| New patient visit (15+ min) | 43 | $2,332 | $54 |
| Destruction of precancer skin growth, 2-14 growths | 60 | $844 | $3 |
| Short return visit | 15 | $451 | $28 |
2016: 8 services
| New patient visit (30+ min) | 45 | $3,038 | $68 |
| Short return visit (20+ min) | 40 | $1,935 | $45 |
| Destruction of precancer skin growth, 1 growth | 30 | $1,362 | $44 |
| Destruction of skin growth, 1-14 growths | 14 | $1,064 | $66 |
| Biopsy of single growth of skin and/or tissue | 28 | $953 | $33 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $387 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $269 | $2 |
| Short return visit | 11 | $246 | $22 |
Medicaid work
$1,736 in 2024
Medicaid paid $1,736 for 26 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 14 | $1,100 |
| Short return visit (20+ min) | 12 | $636 |
| 2024 | 26 | 2 | 14 | $1,736 |
| 2020 | 91 | 2 | 18 | $3,082 |
| 2019 | 14 | 1 | 14 | $525 |
| 2018 | 90 | 1 | 23 | $2,569 |
See the largest Medicaid services in earlier years
2020
| Short return visit (20+ min) | 77 | $2,428 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 14 | $654 |
2019
| Short return visit (20+ min) | 14 | $525 |
2018
| Short return visit (20+ min) | 90 | $2,569 |
Drugs they prescribed that Part D paid
$237,296
Pharmacies billed $237,296 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 408) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
364 generic and 44 brand-name prescriptions · $237,296 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ivermectin | 14 | $4,388 | $313 |
| Tacrolimus | 15 | $1,728 | $115 |
| Fluorouracil | 18 | $1,584 | $88 |
| Isotretinoin | 12 | $1,396 | $116 |
| Fluocinonide | 21 | $1,180 | $56 |
See all 14 drugs
| Ivermectin | 14 | $4,388 | $313 |
| Tacrolimus | 15 | $1,728 | $115 |
| Fluorouracil | 18 | $1,584 | $88 |
| Isotretinoin | 12 | $1,396 | $116 |
| Fluocinonide | 21 | $1,180 | $56 |
| Tretinoin | 14 | $1,107 | $79 |
| Triamcinolone Acetonide | 39 | $346 | $9 |
| Clindamycin Phosphate | 16 | $339 | $21 |
| Clobetasol Propionate | 15 | $269 | $18 |
| Ketoconazole | 26 | $258 | $10 |
| Hydrocortisone | 40 | $223 | $6 |
| Minoxidil | 38 | $216 | $6 |
| Mupirocin | 13 | $205 | $16 |
| Hydroxyzine | 11 | $115 | $10 |
Year by year
| 2024 | 408 | 126 | 0% (0) | 11% | $237,296 |
| 2023 | 249 | 73 | 0% (0) | 14% | $218,993 |
| 2022 | 392 | 85 | 0% (0) | 17% | $292,407 |
| 2021 | 426 | 122 | None | 12% | $216,345 |
| 2020 | 647 | 168 | 0% (0) | 18% | $245,378 |
| 2019 | 773 | 224 | 0% (0) | 9% | $134,260 |
| 2018 | 865 | 239 | 0% (0) | 9% | $172,241 |
| 2017 | 512 | 151 | 0% (0) | None | $39,686 |
| 2016 | 104 | 37 | 0% (0) | 12% | $8,672 |
| 2015 | 16 | None | None | None | $630 |
| 2014 | 25 | 12 | None | 52% | $1,884 |
| 2013 | 69 | 22 | 0% (0) | 19% | $4,222 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Fluocinonide | 27 | $2,238 | $83 |
| Metronidazole | 11 | $900 | $82 |
| Clindamycin Phosphate | 16 | $836 | $52 |
| Ketoconazole | 34 | $394 | $12 |
| Triamcinolone Acetonide | 14 | $223 | $16 |
| Hydroxyzine | 16 | $181 | $11 |
| Finasteride | 15 | $131 | $9 |
2022: 11 drugs
| Cosentyx Pen (2 Pens) | 12 | $81,697 | $6,808 |
| Jublia | 13 | $9,624 | $740 |
| Fluocinonide | 40 | $3,471 | $87 |
| Ketoconazole | 64 | $1,389 | $22 |
| Metronidazole | 12 | $937 | $78 |
| Clindamycin Phosphate | 15 | $675 | $45 |
| Doxycycline Hyclate | 22 | $637 | $29 |
| Triamcinolone Acetonide | 30 | $393 | $13 |
| Hydrocortisone | 43 | $313 | $7 |
| Hydroxyzine | 12 | $95 | $8 |
| Prednisone | 13 | $68 | $5 |
2021: 12 drugs
| Cosentyx Pen (2 Pens) | 14 | $89,187 | $6,370 |
| Fluocinonide | 49 | $3,321 | $68 |
| Metronidazole | 19 | $1,825 | $96 |
| Clobetasol Propionate | 19 | $1,338 | $70 |
| Ketoconazole | 50 | $1,016 | $20 |
| Valacyclovir | 18 | $830 | $46 |
| Clindamycin Phosphate | 11 | $671 | $61 |
| Doxycycline Hyclate | 28 | $604 | $22 |
| Hydrocortisone | 56 | $496 | $9 |
| Triamcinolone Acetonide | 35 | $495 | $14 |
| Hydroxyzine | 11 | $94 | $9 |
| Prednisone | 12 | $78 | $7 |
2020: 15 drugs
| Humira(Cf) | 11 | $63,908 | $5,810 |
| Dupixent | 12 | $39,823 | $3,319 |
| Metronidazole | 29 | $2,870 | $99 |
| Fluorouracil | 25 | $2,625 | $105 |
| Tacrolimus | 15 | $2,012 | $134 |
| Clobetasol Propionate | 23 | $1,651 | $72 |
| Doxycycline Hyclate | 58 | $1,597 | $28 |
| Fluocinonide | 26 | $1,365 | $52 |
| Ketoconazole | 59 | $1,340 | $23 |
| Triamcinolone Acetonide | 58 | $780 | $13 |
| Clindamycin Phosphate | 17 | $655 | $39 |
| Hydrocortisone | 82 | $523 | $6 |
| Betamethasone Valerate | 16 | $422 | $26 |
| Gabapentin | 21 | $248 | $12 |
| Hydroxyzine | 14 | $177 | $13 |
2019: 19 drugs
| Dupixent | 12 | $35,772 | $2,981 |
| Fluorouracil | 35 | $3,744 | $107 |
| Metronidazole | 28 | $2,574 | $92 |
| Clobetasol Propionate | 33 | $2,314 | $70 |
| Calcipotriene | 14 | $2,250 | $161 |
| Ketoconazole | 95 | $2,183 | $23 |
| Fluocinonide | 37 | $1,922 | $52 |
| Doxycycline Hyclate | 46 | $1,468 | $32 |
| Triamcinolone Acetonide | 80 | $942 | $12 |
| Mycophenolate Mofetil | 17 | $937 | $55 |
| Clindamycin Phosphate | 15 | $905 | $60 |
| Hydrocortisone | 86 | $804 | $9 |
| Clotrimazole | 13 | $523 | $40 |
| Ciclopirox | 17 | $385 | $23 |
| Hydroxyzine | 18 | $336 | $19 |
| Mupirocin | 17 | $190 | $11 |
| Nystop | 11 | $183 | $17 |
| Spironolactone | 11 | $117 | $11 |
| Gabapentin | 17 | $48 | $3 |
2018: 20 drugs
| Clobetasol Propionate | 41 | $10,471 | $255 |
| Fluocinonide | 74 | $5,801 | $78 |
| Fluorouracil | 41 | $4,641 | $113 |
| Doxycycline Hyclate | 49 | $3,812 | $78 |
| Calcipotriene | 16 | $3,642 | $228 |
| Myorisan | 14 | $1,840 | $131 |
| Metronidazole | 15 | $1,738 | $116 |
| Ketoconazole | 66 | $1,490 | $23 |
| Triamcinolone Acetonide | 90 | $1,290 | $14 |
| Desonide | 11 | $1,024 | $93 |
| Ciclopirox | 26 | $828 | $32 |
| Hydrocortisone | 82 | $540 | $7 |
| Prednisone | 50 | $538 | $11 |
| Ammonium Lactate | 16 | $514 | $32 |
| Mometasone Furoate | 11 | $344 | $31 |
| Hydroxyzine | 21 | $279 | $13 |
| Mupirocin | 21 | $253 | $12 |
| Nystop | 14 | $177 | $13 |
| Finasteride | 12 | $129 | $11 |
| Cephalexin | 11 | $86 | $8 |
2017: 15 drugs
| Clobetasol Propionate | 29 | $8,034 | $277 |
| Fluocinonide | 52 | $3,667 | $71 |
| Calcipotriene | 14 | $3,023 | $216 |
| Fluorouracil | 20 | $2,444 | $122 |
| Metronidazole | 14 | $1,498 | $107 |
| Triamcinolone Acetonide | 69 | $1,243 | $18 |
| Ketoconazole | 56 | $1,034 | $18 |
| Doxycycline Hyclate | 22 | $924 | $42 |
| Prednisone | 26 | $395 | $15 |
| Hydroxyzine | 23 | $305 | $13 |
| Ammonium Lactate | 11 | $242 | $22 |
| Hydrocortisone | 24 | $171 | $7 |
| Finasteride | 13 | $116 | $9 |
| Mupirocin | 13 | $110 | $8 |
| Spironolactone | 13 | $80 | $6 |
2016: 3 drugs
| Clobetasol Propionate | 12 | $1,572 | $131 |
| Fluocinonide | 16 | $1,197 | $75 |
| Triamcinolone Acetonide | 13 | $208 | $16 |
2013: 1 drug
| Fluocinonide | 20 | $1,529 | $76 |
Money from drug and device companies
$31 in 2023
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $31 | 2 payments
|
See all 2 published payments
| Pfizer | Education · 2023-05-10 | Cibinqo | $15 |
| Pfizer | Education · 2023-04-12 | Cibinqo | $15 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1992099022
- Licence
- CA A121963California A121963: Current · expires 2028-01-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
- Mailing address
- 450 Broadway St Fl C2, Redwood City, CA, 94063
- NPI first listed
- 2011-06-06
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St Fl C2, Redwood City, CA, 94063